Cold Plasma Trastuzumab Therapy for HER2 Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for HER2-positive breast cancer, such as Trastuzumab, face challenges with resistance and inefficacy in HER2-negative breast cancer, necessitating a novel approach to enhance treatment outcomes for both cell types.
Innovation Solution
Concomitant use of cold atmospheric plasma (CAP) and Trastuzumab to induce oxidative stress and alter signaling pathways, synergistically targeting both HER2-positive and negative breast cancer cells, while sparing normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Trastuzumab is used to treat HER2-positive breast cancer, then targeted therapy efficacy is improved, but treatment resistance develops and efficacy is lost in HER2-negative patients
Solution Approach 1:
The patent combines cold atmospheric plasma (CAP) technology with Trastuzumab antibody therapy to create a synergistic treatment system. CAP generates reactive oxygen species that induce oxidative stress in cancer cells, while Trastuzumab provides targeted binding to HER2 receptors. This combination allows the treatment to effectively target both HER2-positive and HER2-negative breast cancer cells, overcoming the limitation of Trastuzumab alone which only works on HER2-positive cells.
2Adaptability or versatility
If cold plasma is used alone for cancer treatment, then broad applicability to different cancer types is achieved, but selectivity and targeted efficacy are reduced
Solution Approach 1:
The patent uses Trastuzumab as an intermediary agent that specifically binds to HER2 receptors on cancer cells. When combined with cold atmospheric plasma, the Trastuzumab-HER2 complex serves as a targeted platform that concentrates the plasma-induced oxidative stress specifically at HER2-positive tumor sites, thereby enhancing selectivity while maintaining the broad applicability of plasma technology.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances cancer cell death in both HER2-positive and negative cell lines without significant impact on normal cells, overcoming resistance and improving therapeutic efficacy.
Implementation Method 1
Cold atmospheric plasma (CAP) has been intensively investigated recently. It has been proven to be effective in wound healing, sterilization, antifungal treatments, and cancer therapy
Implementation Method 2
CAP will induce intracellular oxidative stress (ROS) generation, which will increase the possibility of cell apoptosis
Implementation Method 3
Trastuzumab, developed by Genentech Inc, is a humanized monoclonal antibody, which binds to the extracellular domain of HER2 and inhibits the proliferation and survival of HER2-dependent tumor
Data Source
AI summary
A system and method for using a concomitant effect of cold atmospheric plasma and Trastuzumab to overcome Trastuzumab invalidity or resistance and enhances the outcome of breast cancer therapy in both HER2-positive and negative cancer cells.